MANAGEMENT DISCUSSION AND ANALYSIS

H1 2026

Table of Contents

01 CEO Message & H1 2026 Key Highlights

02 Overview

03 Operational Highlights

04 Group Income Statement Analysis

05 Detailed Segment Performance

06 Balance Sheet Analysis

07 Cash Flow Analysis

08 Guidance

09 Complex Procedures & Clinical Achievements

10 Appendix

CEO Message

PureHealth delivered a strong first half of 2026, underpinned by broad-based growth across the Care and Cover verticals. Performance and momentum accelerated in the second quarter, supported by higher profitability, stronger operating leverage, and a significant uptick in Q2'26 patient activity after short-term headwinds earlier in the year.

The period also demonstrated the benefits of the Group's diversification. International Care continued to scale, supported by the consolidation of Hellenic Healthcare Group and continued momentum at Circle, while Daman delivered sustained revenue growth through renewals, pricing and customer acquisition. In UAE Care, we continued to expand access, improve utilisation and focus on higher-acuity services, supporting both quality of care and business resilience.

Looking ahead, our priorities are clear: to build on the Q2 momentum, integrate and scale our international operations, capture synergies across the Group, and continue investing in technology, efficiency and advanced clinical capabilities. With a strong UAE foundation, growing international contribution and a more diversified earnings base, PureHealth is well positioned to deliver sustainable value for patients, partners and shareholders.

Key Highlights of H1 2026

Revenue	▲	AED 14.9 Bn +9% YoY	Patient Interactions*	▲	6.1 Mn +21% YoY
EBITDA	▲	AED 2.9 Bn +24% YoY	Operational Beds*	▲	6.9 K +25% YoY
EBITDA Margin	▲	19.3% +2.2 ppts YoY	Inpatient Volume*	▲	163 K +51% YoY
Net Profit	▲	AED 1.2 Bn +20% YoY	Outpatient Volume*	▲	5,443 K +23% YoY
EPS (LTM)	▲	AED 0.20 +28% YoY	UAE Test Volumes	▼	16.2 Mn -3% YoY
Total Assets	▲	AED 57.2 Bn +1% vs FY25	GWP	▲	AED 5.5 Bn +13% YoY

*Figures Include UAE, UK, Cyprus and Greece operations

Overview

Abu Dhabi, July 2026 – PureHealth, the UAE's largest healthcare group with an expanding international footprint, delivered a strong first-half performance in 2026, underscoring the resilience and scalability of its integrated healthcare and insurance platform. Results were supported by continued momentum across the Group's complementary Care and Cover verticals, disciplined execution in the UAE, and the growing contribution of international operations. Together, these drivers reflect the Company's strategic progress in achieving diversified, higher-quality earnings with greater geographic reach, operational depth and long-term value creation potential.

PureHealth operates through two complementary verticals:

Care, which includes Hospitals, Diagnostics, Procurement and Technology, represents the Group's healthcare delivery platform across the UAE and international markets. In the UAE, PureHealth operates the country's largest healthcare network, with more than 20 hospitals and approximately 5,000 licensed beds. Internationally, the platform includes Circle Health Group, the UK's largest private healthcare provider, and Hellenic Healthcare Group, the largest private healthcare provider in Greece and Cyprus.

Cover is anchored by Daman, one of the UAE's leading insurers. Daman's health insurance business covers 3.4 million members and processes more than 56 million claims annually, while its Property & Casualty business continues to scale as part of the Group's broader multi-line insurance strategy.

In H1 2026, PureHealth delivered a strong financial performance:

- **Revenue** increased 9.4% year-on-year (YoY) to AED 14.9 billion, supported by the consolidation of Hellenic Healthcare Group (HHG), which contributed AED 1.6 billion in the first half, alongside continued momentum in Cover and International Care.

- **EBITDA** increased 23.9% YoY to AED 2.9 billion, with EBITDA margin expanding to 19.3% up 2.2pp, reflecting broad-based growth across UAE Care and Cover, alongside the increasing contribution from higher-margin international businesses.

- **Net Income** increased 20.1% YoY to AED 1.2 billion, despite UAE Care regulatory and revenue comparability effects and the short-term headwinds earlier in the year.

Strategic Highlights

UAE Care Momentum

UAE Care activity strengthened in Q2 2026, following short-term headwinds experienced in the first quarter. Outpatient growth accelerated, inpatient momentum remained resilient and utilisation continued to improve across expanded beds, clinics and services. While reported revenue remained affected by regulatory and accounting comparability factors, including the Unified Purchasing Program (UPP) and internal revenue elimination adjustments, underlying operational momentum improved, supported by patient activity, case mix and productivity initiatives.

International Growth Strategy

PureHealth continued to scale its international Care platform through disciplined buy-and-build execution. International Care delivered strong H1 performance, supported by HHG consolidation, the continued growth of Circle and resilient margins. HHG strengthened the Group's exposure to Greece and Cyprus, while Circle continued to benefit from a shift toward higher-acuity, more complex inpatient activity in the UK. International expansion is enhancing PureHealth's revenue diversification, improving the quality of earnings and supporting margin-accretive growth.

Daman Market Share Strategy

Daman continued to execute its market share strategy, prioritising scale, retention and growth across multiple lines of business. Its core health insurance business delivered strong growth, supported by robust client retention and continued new customer acquisition, with active membership increasing 4% year on year to 3.4 million. Profitability remained resilient, with net profit rising 9% year on year, underpinned by disciplined underwriting and effective cost management. The Property & Casualty business also continued to build momentum, particularly across the Energy and Property lines, supported by investments in operational capabilities, technology and specialist talent. Daman remains focused on sustainable growth, claims management, solvency strength and capital efficiency.

Operational Highlights

PureHealth maintained strong operational and strategic momentum in Q2 2026, delivering continued progress across capacity expansion, clinical capability enhancement, technology enablement, insurance growth, and international integration. During the quarter, the Group further strengthened its healthcare ecosystem through the rollout of advanced diagnostics, expansion of specialist services, digital transformation initiatives, and targeted partnerships to support long-term growth. These developments reinforce PureHealth's commitment to delivering high-quality, integrated healthcare while advancing operational excellence across its Care and Cover verticals. Key highlights included:

UAE Care

SEHA, SEHA Clinics and SSMC

PureHealth partners with Aldar on Longevity Living

PureHealth has partnered with Aldar to **explore the integration of health longevity, preventive care, and wellness technologies into residential communities**. The collaboration will combine healthcare expertise, innovation, and community design to support healthier lifestyles and longevity-focused living. Joint research, pilot initiatives, and health outcomes measurement will help advance the UAE's position as a global hub for health longevity and sustainable living

Expanded Advanced Diagnostics and Specialized Care

SEHA expanded advanced diagnostics and specialized outpatient services through the rollout of a comprehensive Lung Cancer Screening Programme at SKMC, strengthening early detection and timely diagnosis. The Group also advanced its clinical technology capabilities with the **acquisition of the Al Ain region's first photon-counting CT, enhancing diagnostic precision** and supporting higher-value radiology volumes.

SEHA also continued to advance complex care capabilities by **successfully performing a complex separation of conjoined twins** through a multidisciplinary team of more than 60 international specialists. The procedure demonstrated SEHA's advanced surgical capabilities and expertise in delivering highly specialized care for complex cases.

SSMC strengthened its high-acuity care capabilities through the expansion of 24/7 trauma coverage and robotic surgery programmes, improving asset utilisation, margin profile and capacity to manage more complex procedures. The hospital also introduced the EndoFLIP 300 system, **supporting clinical differentiation and expanding advanced diagnostic capabilities.**

SSMC further enhanced its specialized care offering by becoming the **first hospital in the UAE to offer BEST™ (Bleomycin Electro sclerotherapy) therapy** for paediatric vascular malformations, expanding its referral base and strengthening clinical differentiation.

PureCS

Building AI-Native Digital and Automation Capabilities

PureCS continues to build AI-native capabilities by embedding automation across core functions (HR, finance, supply chain, contact centres), alongside scaling cybersecurity services and evolving proprietary platforms; supported by enterprise-wide AI adoption initiatives to enhance productivity and enable a unified, data-driven operating model Additionally, **HHG is rolling out PureNet** to enhance clinical workflow efficiency, data integration and throughput in network.

Rafed

The deployment of AI-driven sourcing platforms enhanced procurement operations by improving efficiency, supporting data-driven decision-making, and strengthening supply chain performance.

International Care

Hellenic Healthcare Group

Clinical Capacity and Service Advancement

HHG is advancing capacity and service capabilities through the **expansion of advanced diagnostics**, including next-generation diagnostics PET/CT, and enhancements to hospital infrastructure across key sites. The Group is also **strengthening its specialized care** offering through the **launch of the Pulmonary Nodule Centre and One-Day Clinic**, supported by the expansion of high-acuity services, including **cardiac electrophysiology and stroke care**, as well as internationally **accredited IVF and clinical training** capabilities. These initiatives are complemented by the rollout of **PureNet**, enhancing clinical workflows, strengthening integration across healthcare services, and supporting more efficient, coordinated patient care.

HHG also launched the **University of Nicosia Campus (Athens),** the **first AI-focused medical university campus integrating AI, data analytics, and digital health into medical education**. The initiative strengthens PureHealth's regional workforce capacity by connecting academic training, clinical practice, and research across Greece and Cyprus, further enhancing HHG's role in developing future healthcare professionals.

Circle Health Group

Expanding Capacity and Specialist Capabilities

Circle continued to expand capacity and specialist services by scaling outpatient and diagnostic throughput through enhanced consulting room utilisation and network-wide MRI expansion. The Group also strengthened its high-acuity capabilities through the deployment of a **second Da Vinci 5 surgical** system and the continued rollout of robotic orthopaedics **(MAKO and VELYS).** During the period, Circle completed the **world's first AutoPlan-enabled total knee**

arthroplasty using the VELYS robotic system at The Park Hospital, further reinforcing its leadership in advanced orthopaedic care.

Cover

Daman

P&C Business Update

Daman continued to expand its Property & Casualty business, with revenue growth driven by its Energy and Property portfolio. The business also strengthened operational readiness, with **AED 83 million** in GWP underwritten during H1'26, reflecting early underwriting traction and supporting further diversification of Daman's insurance portfolio.

Group Income Statement Analysis

AED Mn	Q2 2026	Q2 2025	Δ%	H1 2026	H1 2025	Δ%
Revenue	7,588	6,993	+8.5%	14,851	13,574	+9.4%
Cost of sales	(5,648)	(5,433)	+4.0%	(11,232)	(10,266)	+9.4%
Gross profit	1,940	1,560	+24.4%	3,619	3,308	+9.4%
G&A expenses, incl. selling & distribution	(1,080)	(980)	+10.2%	(2,340)	(2,137)	+9.5%
Finance costs	(235)	(179)	+31.3%	(469)	(393)	+19.5%
Other operating income	320	213	+50.4%	593	396	+49.7%
Profit before tax	945	614	+54.0%	1,403	1,175	+19.4%
Income tax expense	(124)	(90)	+37.9%	(167)	(146)	+14.3%
Net Profit for the year	821	524	+56.8%	1,236	1,029	+20.1%
EBITDA	1,687	1,186	+42.2%	2,874	2,319	+23.9%
Gross Profit Margin	25.6%	22.3%	+3.3ppts	24.4%	24.4%	+0.0ppts
EBITDA Margin	22.2%	17.0%	+5.2ppts	19.3%	17.1%	+2.2ppts
Net profit Margin	10.8%	7.5%	+3.3ppts	8.3%	7.6%	+0.7ppts

Segment contribution – H1 2026



+9% YoY ▲
Revenue Growth

+24% YoY ▲
EBITDA Growth

+20% YoY ▲
Net Profit

+51% YoY ▲
Inpatient Footfall

+23% YoY ▲
Outpatient Footfall

+33 % YoY ▲
Radiology Volumes

Group revenue increased 9.4% YoY to AED 14.9 billion in H1 2026, with Q2 revenue up 8.5% YoY to AED 7.6 billion. Growth was supported by the consolidation of HHG, which contributed AED 1.6 billion in H1 2026, alongside continued momentum across Cover and International Care.

In UAE Care, patient volumes improved over the course of Q2, reflecting heightened activity during the quarter. Reported revenue, however, continued to be affected by regulatory and comparability factors, including UPP.

International Care continued to deliver strong revenue and EBITDA growth, driven by HHG consolidation, continued Circle growth and resilient margins across the international portfolio. Performance was further supported by sustained patient demand and a continued shift towards higher-acuity, more complex inpatient care.

The Cover segment continued to deliver a resilient performance, supported by robust policy renewals, disciplined pricing and new customer acquisition, while maintaining focus on underwriting discipline and long-term platform value.

Q2 performance strengthened materially, supported by continued momentum in Cover, the scaling of International Care following HHG consolidation, and increasing activity in UAE Care.

Group EBITDA increased 23.9% YoY to AED 2.9 billion in H1 2026, with Q2 EBITDA up 42.2% YoY to AED 1.7 billion, reflecting the growing contribution from higher-margin international operations and continued cost discipline across segments.

Group net profit increased 20.1% YoY to AED 1.2 billion in H1 2026, with Q2 net profit up 56.8% YoY to AED 821 million, demonstrating stronger profitability and operating leverage despite UAE Care regulatory and revenue comparability effects and the short-term headwinds earlier in the year.

Detailed Segment Performance

Care

AED Mn	Q2 2026	Q2 2025	Δ%	H1 2026	H1 2025	Δ%
Revenue	5,484	5,101	+7.5%	10,724	9,818	+9.2%
Total OPEX	(4,865)	(4,710)	+3.3%	(9,821)	(8,982)	+9.3%
EBITDA	1,356	888	+52.7%	2,321	1,811	+28.2%
EBITDA margin	24.7%	17.4%	+7.3 ppts	21.6%	18.4%	+3.2 ppts
Profit Before Tax	630	330	+90.7%	881	696	+26.7%
Net Profit	548	276	+98.2%	778	607	+28.2%
Net Profit margin	10.0%	5.4%	+4.6ppts	7.3%	6.2%	+1.1ppts

9% YoY ▲

Revenue Growth

22% ▲

EBITDA Margin

6.1 Mn ▲

Patient Interactions

4.2 Mn ▲

UAE Patient Interactions

1.9 Mn ▲

International Patient Interactions

Care revenue grew by 9.2% YoY to AED 10.7 billion in H1 2026, with Q2 2026 revenue increasing by 7.5% to AED 5.5 billion, supported primarily by HHG consolidation and continued growth across the international portfolio, alongside growing patient activity in UAE Care.

Growth was further supported by higher patient activity across both UAE and international operations, reflecting ongoing service expansion, capacity additions and broader clinical activity across the platform.

EBITDA increased by 28.2% YoY to AED 2.3 billion in H1 2026, driven by higher-margin international assets, a favorable business mix and continued efficiency gains.

Q2 performance strengthened materially, with EBITDA increasing 52.7% YoY and margin expanding to 24.7%, supported by HHG consolidation, an improvement in UAE Care profitability, operational execution, and favourable movements in expected credit losses.

Net profit increased by 28.2% YoY to AED 778 million in H1 2026, while Q2 2026 net profit increased by 98.2% to AED 548 million, reflecting improved operating leverage, the expanded international contribution and volume-related benefits in UAE Care.

Cover

AED Mn	Q2 2026	Q2 2025	Δ%	H1 2026	H1 2025	Δ%
Revenue	2,105	1,892	+11.2%	4,127	3,756	+9.9%
Total OPEX	(1,864)	(1,703)	+9.4%	(3,751)	(3,421)	+9.7%
EBITDA	331	298	+10.9%	552	509	+8.5%
EBITDA margin	15.7%	15.8%	-0.1 ppts	13.4%	13.5%	-0.1ppts
Profit Before Tax	315	283	+11.3%	521	479	+8.8%
Net Profit	273	247	+10.5%	458	422	+8.6%
Net Profit margin	13.0%	13.1%	-0.1 ppts	11.1%	11.2%	-0.1ppts.

+10% YoY ▲
Revenue Growth

+13% YoY ▲
GWP Growth

13% ▲
EBITDA Margin

3.4 M ▲
Active Members

189% ▲
Solvency Ratio

Cover delivered solid top-line growth in H1 2026, with revenue rising by 9.9% YoY to AED 4.1 billion, while Q2 2026 revenue increased by 11.2% to AED 2.1 billion**.** Growth was supported by a 13% increase in gross written premiums (GWP), driven by strong policy renewals, disciplined pricing and new customer acquisition. Daman's active membership reached 3.4 million, representing a 4% YoY increase.

Property and Casualty (P&C) continued to gain traction, generating AED 83 million of GWP in H1'26 as all product lines gained traction and broadened Daman's multi-line offering.

EBITDA increased by 8.5% YoY to AED 552 million in H1 2026, while Q2 2026 EBITDA increased by 10.9% to AED 331 million, reflecting continued underwriting discipline and effective cost management alongside investment in growth.

Net profit increased by 8.6% YoY to AED 458 million in H1 2026, while Q2 2026 net profit increased by 10.5% to AED 273 million, supported by consistent operating performance and continued momentum across the insurance portfolio.

Balance Sheet Analysis

AED Mn	H1 2026	FY 2025	Δ%
Total Non-Current Assets	37,223	36,657	+2%
Right of use assets	12,123	12,671	-4%
Intangible Assets	12,291	12,568	-2%
Property & equipment	7,222	7,397	-2%
Other non-current assets	5,587	4,020	+39%
Total Current Assets	19,964	20,021	0%
Trade & other receivables	8,657	5,923	+46%
Cash & Bank Balance	4,730	7,706	-39%
Reinsurance contract assets	1,762	1,586	+11%
Other current Assets	4,815	4,806	0%
Total Assets	**57,187**	**56,678**	**+1%**
Total Non-Current Liabilities	22,724	22,944	-1%
Lease liabilities	13,625	13,870	-2%
Borrowings	2,882	2,834	+2%
Employee end of service Benefits	1,666	1,621	+3%
Other non-current liabilities	4,551	4,619	-1%
Total Current Liabilities	15,656	15,412	+2%
Trade & other payables	9,087	9,294	-2%
Lease liabilities	1,193	1,106	+8%
Contract liability	70	61	+15%
Borrowings	333	415	-20%
Other current liabilities	4,974	4,537	+10%
Total Liabilities	**38,379**	**38,356**	**0%**
Total Equity	**18,807**	**18,322**	**+3%**
Total Liabilities & Equity	**57,187**	**56,678**	**+1%**

AED Mn	H1 2026	FY 2025	Δ%
Total Bank Debt	3.2	3.2	-1.1%
Bank Debt to Equity	0.2x	0.2x	0.0x
Cash & Bank Balance	4,730	7,706	-39%
Net Debt (Incl. lease liabilities adjusted for restricted cash)	14,155	11,780	+20%
Total Lease Liabilities	14,818	14,976	-1%
Net Debt / EBITDA	**2.7x**	**2.5x**	**+0.2x**

The Group continues to maintain a robust financial position, underpinned by total assets of AED 57.2 billion, providing a strong foundation to support its strategic priorities and ongoing investment agenda. **Cash and bank balances of AED 4.7 billion continue to provide strong liquidity to support operational requirements**. Net debt increased to 14.2 billion, primarily driven by lower Cash and cash equivalent balances, while bank debt remained broadly stable at AED 3.2 billion. **Net debt-to-EBITDA stood at 2.7x** on a post-IFRS 16 basis, reflecting a **prudent leverage profile** following recent acquisitions and continued capital deployment. Overall, the Group remains well positioned to pursue value accretive growth opportunities, supported by disciplined capital management and a resilient financial structure.

Cash Flow Analysis

AED Mn	Q2 2026	Q2 2025	Δ%	H1 2026	H1 2025	Δ%
Net Profit for the period before tax	945	614	+54%	1,403	1,175	+19%
Non-cash Adjustments	670	562	+19%	1,403	1,155	+21%
Working Capital Changes[3]	(229)	601	-138%	(3,217)	(2,699)	+19%
Employees' end of service benefits paid net	(37)	(52)	-29%	(86)	(101)	-15%
Other	(569)	(199)	+186%	117	1,142	-90%
Net cash, operating activities	780	1,526	-49%	(380)	672	-157%
Net cash, investing activities	(240)	(671)	-64%	(737)	(1,624)	-55%
Net cash, financing activities	(589)	(529)	+11%	(732)	(2,608)	-72%
Net change in cash & cash equivalents during the period	(49)	326	-115%	(1,850)	(3,560)	-48%
FX rate changes during the period	(9)	52	-118%	(21)	78	-127%
Cash & cash equivalents at the beginning of the period	2,612	4,929	-47%	4,424	8,789	-50%
Cash & cash equivalents at the end of the period	**2,553**	**5,307**	**-52%**	**2,553**	**5,307**	**-52%**

In H1 2026, the Group recorded AED 380 million in negative cash flow from operations, compared with a positive operating cash flow of AED 672 million in H1 2025. The decline was primarily driven by **working capital movements, reflecting the usual timing of receivables balances and the Group's seasonal cash conversion cycle**. Other operating activities were affected by movements in restricted cash and insurance contract balances, which are timing-related and cyclical in nature. **Growth capex increased in line with the Group's ongoing investment in expanding capacity, enhancing services and advancing strategic priorities** across local and international operations.

The Group remains focused on improving cash conversion, with a **steady improvement expected as the year progresses, while maintaining disciplined investment behind its long-term growth priorities.**

[3] Working capital does not include reinsurance contract assets/liabilities, other liabilities and restricted cash.

Guidance

Medium-term Financial and Strategic Targets

Medium-term targets remain unchanged, supported by resilient execution and confidence in the Group's growth outlook

	H1 2026	Medium-Term Target (2026-2029)
Revenue Growth (vs prior period)	9.4%	Mid- to High teens *(Including M&A)*
International Revenue Share [4]	33%	c.50%
Care: EBITDA Margin Medium-term target applicable specifically to Healthcare and in view of continued Group-wide M&A activity	21.6%	Low 20s
CAPEX as % of Revenue	3.1%	<5%
Net Debt [5] / EBITDA	2.7x	3.0x
Dividend Payout Ratio	n.a	30%

[4] Share of international business as % of revenue, after intercompany eliminations.
[5] Incl. lease liabilities, adjusted for restricted cash items.

Complex Procedures and Clinical Achievements

SEHA & SSMC

- In H1 2026, performed 7 liver and 66 kidney transplants, bringing the total liver transplants since inception to 40 and kidney transplants to 864.
- Advanced surgical capabilities were demonstrated, with the successful separation of conjoined twins through a multidisciplinary collaboration involving more than 60 international specialists, enabling independent living and face-to-face interaction for the first time.
- Maternal-fetal care capabilities were strengthened, through the successful completion of 24 complex placenta accreta surgeries and highly specialized intrauterine fetal transfusion procedures.
- Advanced clinical technology capabilities expanded, with the acquisition of the Al Ain region's first photon-counting CT, enhancing diagnostic precision and supporting higher-value radiology volumes.
- Robotic surgical innovation advanced, with SSMC performing its first robot-assisted retroperitoneal lymph node dissection (RPLND), expanding complex urologic oncology capabilities.
- Complex trauma and neurocritical care capabilities were demonstrated, with successful multidisciplinary management of advanced neurocritical and trauma reconstruction cases.

Circle Health & Hellenic Healthcare

- Cytoreductive surgical activity progressed, with 43 procedures completed for pseudomyxoma and 26 for colorectal peritoneal carcinomatosis.
- Complex cardiac capabilities progressed, with 38 valve repairs/replacements and 15 TAVI procedures delivered year-to-date, alongside CHG's first VELYS robotic-assisted total knee replacement using advanced automated planning technology.
- Robotic surgical innovation advanced, with Metropolitan Hospital successfully performing Greece's first robotic single-port total hysterectomy for gynaecologic oncology using the da Vinci SP® system.
- Structural heart intervention capabilities demonstrated, with Apollonion Private Hospital successfully performing Cyprus' first Transcatheter Tricuspid Valve Replacement (TTVR) using the EVOQUE™ valve system.

Appendix

H1 2026 Segment Value & Contribution in %



Corporate Structure

Care

Hospital and Other Related Services ("Hospitals")	**UAE:** - Abu Dhabi Health Services Company ("SEHA") - SEHA Clinics (formerly "Ambulatory Healthcare Services") - Sheikh Shakhbout Medical City ("SSMC") - The Medical Office ("TMO") - National Rehabilitation Center ("NRC") - Tamouh Healthcare - The Life Corner Dawak **International:** - Circle Health Group - Hellenic Healthcare Group - Ardent Health Partners Inc (classified as a minority equity investment (21%)
Diagnostic Services	- PureLab
Procurement and Supply of Medical Related Products	- Rafed - One Health
Technology Services and Others	- Pure CS - Talent One

Cover

Insurance Services	- National Insurance Company ("Daman")

About PureHealth

PureHealth (PureHealth Holding PJSC, listed on the Abu Dhabi Securities Exchange: PHH) is the largest healthcare provider in the United Arab Emirates and a leader in the healthcare sector across the MENA region. The Group operates a diverse portfolio that includes over 110 hospitals, over 13,000 licensed beds, insurance, and 143+ laboratories. With its headquarters in Abu Dhabi, PureHealth employs a global team of over 67,000 healthcare practitioners, administrators, and support staff. In 2025, PureHealth catered to around 3.4 million insured members and processed over 56 million insurance claims. As the region's only vertically integrated healthcare platform, PureHealth is committed to transforming healthcare delivery through continuous innovation, operational excellence, and sustainable practices to enhance the well-being of the communities it serves.

Institutional Investor Contact

PureHealth Investor Relations

ir@purehealth.ae

+971 2 2018200

+971 2 2018201

Corporate Headquarters Address

PureHealth Headquarters

Aldar HQ Building,

Al Rahah Street,

Abu Dhabi, UAE

Disclaimer

All information included in this document is for general use only and has not been independently verified, nor does it constitute or form part of any invitation or inducement to engage in any investment activity, nor does it constitute an offer or invitation or recommendation to buy or subscribe for any securities in the United Arab Emirates, or an offer or invitation or recommendation in respect of buying, holding or selling any securities of PureHealth Holding PJSC.

No representation or warranty, express or implied, is made by PureHealth Holding PJSC as to the fairness, accuracy, completeness, or correctness of the information or opinions contained in this document, and no reliance should be placed on them for any purpose. To the extent permitted by applicable law, PureHealth Holding PJSC disclaims any liability arising from the use of, or reliance on, this document or its contents.

This document may include statements that are, or may be deemed to be, "forward-looking statements" with respect to the Group's financial position, results of operations and business. Information on the Group's plans, intentions, expectations, assumptions, goals and beliefs are for general update only and do not constitute or form part of any invitation or inducement to engage in any investment activity, nor does it constitute an offer or invitation or recommendation to buy or subscribe for any securities in any jurisdiction, or an offer or invitation or recommendation in respect of buying, holding or selling any securities of PureHealth Holding PJSC.